| Identification | Back Directory | [Name]
4-[3-[4-Cyano-3-(trifluoroMethyl)phenyl]-5,5-diMethyl-4-oxo-2-thioxo-1-iMidazolidinyl]-2-fluoro-N-(Methyl-d3)benzaMide | [CAS]
1443331-82-5 | [Synonyms]
MDV 3100-d3
[2H3]-MDV 3100
[2H3]-Enzalutamide
4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-(methyl-d3)benzamide
4-[3-[4-Cyano-3-(trifluoroMethyl)phenyl]-5,5-diMethyl-4-oxo-2-thioxo-1-iMidazolidinyl]-2-fluoro-N-(Methyl-d3)benzaMide | [Molecular Formula]
C21H13D3F4N4O2S | [MDL Number]
MFCD29045174 | [MOL File]
1443331-82-5.mol | [Molecular Weight]
467.454 |
| Chemical Properties | Back Directory | [Melting point ]
196-199°C | [storage temp. ]
Refrigerator | [solubility ]
Chloroform (Slightly), Ethyl Acetate (Slightly) | [form ]
Solid | [color ]
Off-White to Pale Yellow |
| Hazard Information | Back Directory | [Uses]
Labelled MDV 3100. MDV 3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer. | [References]
[1] Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324(5928):787-90. DOI:10.1126/science.1168175 |
|
|